Do you want to read an article? Please log in or register.
Endocrine therapy and risk of cardiovascular disease and mortality in postmenopausal breast cancer survivors
Breast Cancer
Related content
ESMO 2024
Breast Cancer
ABIGAIL: Abemaciclib plus endocrine therapy improves ORR versus paclitaxel in patients with advanced HR+/HER2- breast cancer with aggressive disease criteria
Breast Cancer
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2- early breast cancer: final invasive disease-free survival results from the NATALEE trial
Ann Oncol
Hortobagyi GN, Lacko A, Sohn J, Cruz F, Borrego MR, Manikhas A, Park YH, Stroyakovskiy D, Yardley DA, Huang CS, Fasching PA, Crown J, Bardia A, Chia S, Im SA, Martin M, Loi S, Xu B, Hurvitz S, Barrios C, Untch M, Moroose R, Visco F, Parnizari F, Zarate JP, Li Z, Waters S, Chakravartty A, Slamon D
doi: 10.1016/j.annonc.2024.10.015
Further Publications
The burden of cardiovascular disease and risk for subsequent major adverse cardiovascular events in survivors of childhood cancer: a prospective, longitudinal analysis from the St Jude Lifetime Cohort Study
Lancet Oncol
Hammoud RA, Liu Q, Dixon SB, Onerup A, Mulrooney DA, Huang IC, Jefferies JL, Rhea IB, Ness KK, Ehrhardt MJ, Hudson MM, Ky B, Bhakta N, Sapkota Y, Yasui Y, Armstrong GT
doi: 10.1016/S1470-2045(24)00157-8
Breast Cancer
Breast conserving surgery with intraoperative electron beam radiation therapy for low-risk breast cancer: Five-year follow-up of 306 patients
Int J Cancer
de Jonge C, Schipper RJ, Walstra CJEF, Van Riet YE, Verrijssen AE, Voogd AC, van der Sangen MJC, Theuws J, Degreef E, Gielens MPM, Bloemen JG, van den Berg HA, Nieuwenhuijzen GAP
doi: 10.1002/ijc.35033
RECOMMENDED
Breast Cancer
Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
Lancet Oncol
Meattini I, De Santis MC, Visani L, Scorsetti M, Fozza A, Meduri B, De Rose F, Bonzano E, Prisco A, Masiello V, La Rocca E, Spoto R, Becherini C, Blandino G, Moscetti L, Colciago RR, Audisio RA, Brain E, Caini S, Hamaker M, Kaidar-Person O, Lambertini M, Marrazzo L, Saieva C, Spanic T, Strnad V, Wheelwright S, Poortmans PMP, Livi L, EUROPA Trial Investigators
doi: 10.1016/S1470-2045(24)00661-2
ASCO 2024
Gynecologic Cancer
Estrogen-only hormone therapy may increase ovarian cancer risk, while estrogen-progestin combination may lower the risk of endometrial cancer
Breast Cancer
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancer
Breast
Pagan E, Ruggeri M, Bianco N, Bucci EO, Graffeo R, Borner M, Giordano M, Gianni L, Rabaglio M, Freschi A, Cretella E, Seles E, Farolfi A, Simoncini E, Ciccarese M, Rauch D, Favaretto A, Honecker F, Berardi R, Franzetti-Pellanda A, Gelber S, Partridge AH, Goldhirsch A, Bagnardi V, Pagani O, Ribi K
doi: 10.1016/j.breast.2024.103765
Breast Cancer
Second Primary Breast Cancer in Young Breast Cancer Survivors
JAMA Oncol
Brantley KD, Rosenberg SM, Collins LC, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Warner E, Come SE, Zheng Y, Kirkner GJ, Snow C, Winer EP, Partridge AH
doi: 10.1001/jamaoncol.2024.0286
COMMENTED
Breast Cancer
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
★ 2
Recommended and commented by
Prof. Dr Beat Thürlimann, Faculty Member
N Engl J Med
Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O'Shaughnessy JA, Wildiers H, Pierga JY, Zhang Q, Saura C, Biganzoli L, Sohn J, Im SA, Lévy C, Jacot W, Begbie N, Ke J, Patel G, Curigliano G, DESTINY-Breast06 Trial Investigators
doi: 10.1056/NEJMoa2407086